Clinicopathological Study of 35 Cases of Multiple System Atrophy
JNNP 58:160-166, Wenning,G.K.,et al, 1995
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
N-Methyl-D-Aspartate Antagonists in the Treatment of Parkinson's Disease
Arch Neurol 48:977-981, Greenamyre,J.T.&O'Brien,C.F., 1991
United Parkinson Foundation Neurotransplantation Registry on Adrenal Medullary Transplants:Presurg, & 1-and 2-yr Follow-up
Neurol 41:1719-1722, Goetz,C.G.,et al, 1991
Transplantation in Parkinson's Disease:Two Cases of Adrenal Medullary Grafts to the Putamen
Ann Neurol 22:457-468, Lindvall,O.,et al, 1987
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
Suicide and Suicide Attempts after Subthalamic Nucleus Stimulation in Parkinson Disease
Neurol 93:e97-e105, Giannini, G.,et al, 2019
Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of DIagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality
AJNR 36:2010-2016, Noh, Y.,et al, 2015
Long-Term Clinical Outcomes After Fetal Cell Transplantation in Parkinson Disease Implications for the Future of Cell Therapy
JAMA 311:617-618, Bega, D. & Krainc, D., 2014
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Dementia and Survival in Parkinson Disease: A 12-Year Population Study
Neurol 70:1017-1022, Buter,T.C.,et al, 2008
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Attempted and Completed Suicides After Subthalamic Nucleus Stimulation for Parkinsons Disease
JNNP 79:952-954, Soulas,T.,et al., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Nonsteroidal Anti-Inflammatory Drugs and the Incidence of Parkinson Disease
Neurol 66:1097-1099, Hernan,M.A.,et al, 2006
Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006
Parkinson's Disease
Lancet 363:1783-1793, Samii,A.,et al, 2004
Stem Cells and Neurological Disease
JNNP 74:553-557, Barker,R.A.,et al, 2003
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol 60:1059-1064,1043, Chen,H.,et al, 2003
A Double-Blind Controlled Trial of Bilateral Fetal Nigral Transplantation in Parkinson's Disease
Ann Neurol 54:403-414, Olanow,C.W.,et al, 2003
Effect on Mood of Subthalamic DBS for Parkinson's Disease
Neurol 59:1427-1429, Berney,A.,et al, 2002
Parkinsonism as the Presenting Manifestation of HIV Infection: Improvement on HAART
Neurol 56:278-279, Hersh,B.P.,et al, 2001
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
NEJM 344:710-719,763, Freed,C.R.,et al, 2001
Stem-Cell Research: Drawing the Line
Lancet 358:163,217, Greenberg,D.S., 2001
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Surgery for Parkinson Disease
Arch Neurol 57:1118-1125, Lang,A.E., 2000
Selegiiline and Mortality in Subjects with Parkinson's Disease
Neurol 55:1785-1789,1770, Donnan,P.T.,et al, 2000
Mortality Cancer Risk in Parkinsonian Patients:A Population-Based Study
Neurol 52:395-398, Vanacore,N.,et al, 1999
Long-Term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease
Arch Neurol 56:179-187, Hauser,R.A.,et al, 1999
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's Disease
NEJM 341:988-992, Freeman,T.B.,et al, 1999
Unilateral Pallidotomy for Parkinson's Disease:Results after More Than 1 Year
JNNP 67:511-517, Schrag,A.,et al, 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Evaluation of Surgery for Parkinson's Disease, A Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 53:1910-1921, Hallett,M.,et al, 1999
Botulinum Toxin is a Useful Treatment in Excessive Drooling of Saliva
JNNP 67:697, Bhatia,K.P.,et al, 1999
Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Hereditary Form of Parkinsonism-Dementia
Ann Neurol 43:768-781, Muenter,M.D.,et al, 1998
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Clinical Usefulness of Magnetic Resonance Imaging in Multiple System Atrophy
JNNP 65:65-71, Schrag,A.,et al, 1998
Effect of Selegiline on Mortality in Patients with Parkinson's Disease
Neurol 51:825-830, Olanow,C.W.,et al, 1998
Olfactory Dysfunction in Guamanian ALS,Parkinsonism,and Dementia
Neurol 51:1672-1677, Ahlskog,J.E.,et al, 1998
Surgery for Parkinson's Disease
JNNP 62:2-8, Obeso,J.A.,et al, 1997
Mortality from Parkinson Disease
Arch Neurol 54:260-264, Louis,E.D.,et al, 1997
Clinical Characteristics of a Chromosome 17-Linked Rapidly Progressive Familial Frontotemporal Dementia
Arch Neurol 54:539-544, Basun,H.,et al, 1997
Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People
NEJM 334:71-76, Bennett,D.A.,et al, 1996